Research, Science and Treatments

Results Show Encouraging Survival Data: Nintedanib for Mesothelioma

On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]


BREAKING NEWS FROM ASCO: Promising Results Released from Mesothelioma Clinical Trial

This morning, Arnaud Scherpereel, MD, PhD, head of the Pulmonary and Thoracic Oncology Department at the University Hospital of Lille in France, presented the results of the IFCT-1501 MAPS-2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study was sponsored by the French Cooperative Thoracic Intergroup (IFCT) with drugs and […]



Disparities and Low Participation in Clinical Trials

by Jadmin Mostel, Patient Support and Research Assistant, Mesothelioma Applied Research Foundation
This past March, I attended the National Comprehensive Cancer Network (NCCN) annual conference, and observed a dynamic roundtable discussion about disparities in the medical field. As the conversation was first colored with various factors such as socioeconomic background and language barriers, the conversation took […]


Omnibus Bill Passes, Funds Available to Mesothelioma Research Increase

With the passage of the Omnibus budget bill last week, mesothelioma research will now be eligible for $60 million, an increase of $10 million over the amount previously available.
This particular funding is available through the Department of Defense’s Peer-Reviewed Cancer Research Program (PRCRP), a pot of funding available annually to researchers studying any one of […]